Prescribing of psychotropic medication to the intellectually disabled by community paediatricians - A survey

Child: Care, Health and Development

Volumn 35, Issue 6, 2009, Pages 826-831

  Elliott, S J ^a   Haider, B B ^b  

^a The Alders   (United Kingdom)

^b FAIRFIELD GENERAL HOSPITAL   (United Kingdom)

Author keywords

Children; Community paediatrician; Learning disability; Prescribing; Psychotropic medication

Indexed keywords

ALIMEMAZINE TARTRATE; ATOMOXETINE; CARBAMAZEPINE; CITALOPRAM; CLONIDINE; DEXAMPHETAMINE; FLUOXETINE; MELATONIN; METHYLPHENIDATE; NEUROLEPTIC AGENT; PROMETHAZINE; PSYCHOTROPIC AGENT; RISPERIDONE; TRIAZOLAM; TRIFLUOPERAZINE; ZOPICLONE;

ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; COMMUNITY MEDICINE; DEPRESSION; HEALTH CARE ACCESS; HEALTH SURVEY; INTELLECTUAL IMPAIRMENT; MEDICAL EDUCATION; MEDICAL SPECIALIST; MENTAL HEALTH CARE; PEDIATRICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; SLEEP DISORDER;

ADOLESCENT; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; CHILD, PRESCHOOL; CLINICAL COMPETENCE; FAMILY PRACTICE; HUMANS; MENTAL RETARDATION; PEDIATRICS; PROFESSIONAL PRACTICE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; QUESTIONNAIRES; SLEEP DISORDERS;

EID: 70350521749     PISSN: 03051862     EISSN: 13652214     Source Type: Journal    
DOI: 10.1111/j.1365-2214.2008.00932.x     Document Type: Article

References (25)

1. Aman M G, De Smedt G, Derivan A, Lyons B, Findling R L. Double blind placebo controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. The American Journal of Psychiatry 2002, 159:1337-1346.
2. Chloral hydrate: a risky old psychotropic drug. Prescrire International 1998, 7:88-89. Anonym
3. Bryenwski J, Duggan L. Antipsychotic Medication for Challenging Behaviour in People with Learning Disability 2005, The Cochrane Library, issue 4, Chichester, UK
4. Cooper W O, Hickson G B, Fuchs C, Arbogast P G, Ray W A. New users of antipsychotic medications among children enrolled in TennCare. Archives of Paediatrics & Adolescent Medicine 2004, 158:753-759.
5. Cooper W O, Arbogast P G, Ding H, Hickson G B, Fuchs C, Ray W A. Trends in prescribing of antipsychotic medications for U.S. children: national health care survey. Ambulatory Pediatrics 2006, 6:79-83.
6. Correia Filho A G. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44:748-755.
7. DeLong G R, Teague L A, McSwain Kamran M. Effects of fluoxetine treatment in young children with idiopathic autism. Developmental Medicine and Child Neurology 1998, 40:551-562.
8. Didden R. Sleep problems and daytime problem behaviours in children with intellectual disability. Journal of Intellectual Disability Research 2002, 46:537-547.
9. Emslie G J, Ryan N D, Wagner K D. Major Depressive Disorder in Children and Adolescents: clinical trial design and antidepressant efficacy. Journal of Clinical Psychiatry 2005, 66(7):14-20. Suppl.
10. Einfeld S L, Tongue B L. Population prevalence of psychopathology in children and adolescents with intellectual disability: 11. Epidemiological findings. Journal of Intellectual Disability Research 1996, 40:99-109.
11. Fatem S H, Realmuter G M, Khan L, Thomas P. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. Journal of Autism and Developmental Disorders 1998, 28:303-307.
12. Gralton E J F, James D H, Lindsey M P. Antipsychotic medication, psychiatric diagnosis and children with intellectual disability: a 12 year follow up study. Journal of Intellectual Disability Research 1998, 42:49-57.
13. Greenhill L L, Pliszka S, Dulcan M K, Bernet W, Arnold V, Beitchman J, Benson R S, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw J A, Stock S. Practice parameter for the use of stimulant medications in the treatment of children, adolescents and adults. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41(2):26s-49s. Suppl.
14. Hastings R P, Beck A, Daley D, Hill C. Symptoms of ADHD and their correlates in children with intellectual disabilities. Research in Developmental Disabilities 2004, 26:456-468. Epub Dec 15
15. Hogg J. The administration of psychotropic and anticonvulsant drugs to children with profound intellectual disability and multiple impairments. Journal of Intellectual Disability Research 1992, 36:473-488.
16. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism. Neuropsychopharmacology 2005, 30:582-589.
17. McNicholas F. Psychotropic prescribing practices of paediatricians in the UK. Child: care, health and development 2001, 27:497-508.
18. Pearson D A, Santos C W, Roache J D, Casat C D, Loveland K A, Lachar D, Lane D M, Faria L P, Cleveland LA. Treatment effects of methylphenidate on behavioural adjustment in children with mental retardation and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42:209-216.
19. Pliszka S R. Non-stimulant treatment of attention - deficit/hyperactivity disorder. CNS Spectrums 2003, 8:253-258.
20. Psychiatric Services for Children and Adolescents with Learning Disabilities 2004, Royal College of Psychiatrists, Council Report, Royal College of Psychiatrists, London, UK
21. Rutter M, Tizrd J, Whitmore K. Education, Health and Behaviour 1970, (eds), Longman , London, UK
22. Stores G. Medication for sleep - wake disorders. Archives of Disease in Childhood 2003, 88:899-903.
23. Tarsay D, Balessarini R J, Tarazi F I. Effects of newer antipsychotics on extrapyramidal function [second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2002, 17:202.
24. 1999, The Royal College of Paediatrics and Child Health, Child in mind' project - Royal College of Paediatrics and Child Health Annual General Meeting
25. Turgay A, Binder C, Snyder R, Firman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behaviour disorders in children with subaverage IQs. Pediatrics 2002, 110:e34.